DUBLIN--(BUSINESS WIRE)--The "Global Hemophilia A Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering.
The hemophilia A therapeutics market will register a CAGR of almost 7% by 2023.
Emerging novel convenient approaches to drive market growth
Several novel therapies are emerging in the global hemophilia A therapeutics market. These therapies offer long lasting therapeutics benefits and some of the m possess potential to cure this disorder.
Rising prevalence of hemophilia A
Hemophilia A is a rare genetic disorder, and the incidence of this disorder is gradually increasing. Hemophilia A accounts for about 80% of cases globally and mainly affects men.
High costs of hemophilia A therapeutics
High costs associated with drugs that treat hemophilia A are one of the biggest challenges faced by the market.
Key Players
- Bayer
- CSL
- Novo Nordisk
- Pfizer
- Shire
Topics Covered
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
- Market ecosystem
- Market characteristics
- Market segmentation analysis
PART 04: PIPELINE ANALYSIS
PART 05: MARKET SIZING
- Market definition
- Market sizing 2018
- Market size and forecast 2018-2023
PART 06: FIVE FORCES ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
- Market segmentation by product
- Comparison by product
- Recombinant therapies - Market size and forecast 2018-2023
- Plasma-derived therapies - Market size and forecast 2018-2023
- Hormonal therapies - Market size and forecast 2018-2023
- Others - Market size and forecast 2018-2023
- Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: MARKET SEGMENTATION BY TYPE
- On demand treatment
- Prophylactic treatment
- Inhibitor treatment
PART 10: GEOGRAPHIC LANDSCAPE
- Geographic segmentation
- Geographic comparison
- Americas - Market size and forecast 2018-2023
- EMEA - Market size and forecast 2018-2023
- APAC - Market size and forecast 2018-2023
- Key leading countries
- Market opportunity
PART 11: DRIVERS AND CHALLENGES
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
- Overview
- Landscape disruption
PART 14: VENDOR ANALYSIS
- Vendors covered
- Vendor classification
- Market positioning of vendors
- Bayer
- CSL
- Novo Nordisk
- Pfizer
- Shire
For more information about this report visit https://www.researchandmarkets.com/research/bkvl62/hemophilia_a?w=4
